Brain tumor surgery: new drug may cut stroke risk
NCT ID NCT07520370
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the anti-inflammatory drug ulinastatin can prevent strokes in people having brain tumor removal. About 1,370 patients will receive either ulinastatin or a placebo before and after surgery. The goal is to see if the drug lowers the chance of having a stroke within a week after the operation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ulinastatin (an anti-inflammatory drug given intravenously)
What this could lead to
If it works, this could provide a simple way to reduce stroke risk after brain tumor surgery, improving recovery and safety.
What could go wrong
This is a single-center trial that hasn't started yet. The drug may not reduce strokes, and there is a small risk of allergic reactions or side effects from the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••